Nuvectis Pharma (NVCT) Stock: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$23.99
1.50 (6.67%)
â˛
5d:
-1.56%
30d:
+22.77%
90d:
+128.26%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NVCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NVCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $23.99, which is considered slightly high relative to its 30-day fair value range of $19.77 to $24.43.
Technical Outlook: Technically, NVCT is in a strong uptrend. Immediate support is located at $22.01, while resistance sits at $25.65. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: NVCT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.40 (+47.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVCT is in a strong uptrend. Immediate support is located at $22.01, while resistance sits at $25.65. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: NVCT scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.40 (+47.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$19.77 -
$24.43
Company Quality Score
44/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
58.3%
All Signals
- BULLISH: Options cheap (IV 16th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 47.6% below Wall St target ($35.40)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.77 -
$24.43
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$3.86
(16.1%)
Support & Resistance Levels
Support Level
$22.01
Resistance Level
$25.65
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-20.83
Wall Street Target
$35.40
(+47.6%)
Share & Embed Analysis
Last updated: September 12, 2026 12:57 PM ET
Data refreshes hourly during market hours. Next update: 1:57 PM
Data refreshes hourly during market hours. Next update: 1:57 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
